International immunopharmacology · 2026
FcRn function alone cannot account for elevated IgG clearance in the Lewis lung carcinoma model of cancer cachexia.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Adeluola Adeoluwa, Thomas Justin, Remaily Bryan, Xie Zhiliang, Kim Kyeongmin, Partey Alexandra D, Young Gregory, Hai Min, Hoelzen Emma, Lee Seolbin, Morris Henry, Jeffrey Faith, Bilgin Melisa, Stanton Camille, Dickess Isaac, Granchie Lauren, Kulp Samuel K, Owen Dwight H, Xiaokui Mo, Ganesan Latha P, Mace Thomas A, Phelps Mitch A, Coss Christopher C
Аннотация
PURPOSE: The neonatal Fc receptor (FcRn) protects IgG-based monoclonal antibodies (mAbs) from catabolism by direct binding within endosomes and facilitates their recycling to extracellular spaces. Elevated clearance of immune checkpoint inhibitors (ICIs) and other IgG-based mAbs is often observed in patients with cachexia phenotypes and is associated with worse outcomes. We sought to understand if FcRn's function is altered in cancer cachexia.
EXPERIMENTAL DESIGN: Clearance of IgGs with different FcRn-binding properties were evaluated in cachectic LLC tumor-bearing (TB) and non-cachectic tumor-free mice in both wild-type and FcRn knockout backgrounds. As macrophage depletion with liposomal clodronate affects IgG pharmacokinetics only in the absence of FcRn function, we compared IgG clearance in LLC-TB and TF mice with and without macrophage ablation to assess changes in FcRn's functional status in cachectic tumor-bearing mice.
RESULTS: We noted that the induction of IgG clearance in the presence of a cachectic tumor was dampened by the lack of FcRn engagement in whole body FcRn knockout mice. As expected, clodronate administration did not significantly affect systemic clearance of FcRn-binding IgG, though it significantly reduced clearance of FcRn-null IgG. More importantly, these effects were consistent in both TF and TB cachectic contexts.
CONCLUSIONS: These results suggest that while FcRn accounts for a portion of the observed changes in IgG pharmacokinetics in cancer cachexia, the functional status of FcRn is not significantly different in healthy mice without tumors compared to those with LLC tumors and associated cachexia, which indicates the potential involvement of FcRn-independent mechanisms.
EXPERIMENTAL DESIGN: Clearance of IgGs with different FcRn-binding properties were evaluated in cachectic LLC tumor-bearing (TB) and non-cachectic tumor-free mice in both wild-type and FcRn knockout backgrounds. As macrophage depletion with liposomal clodronate affects IgG pharmacokinetics only in the absence of FcRn function, we compared IgG clearance in LLC-TB and TF mice with and without macrophage ablation to assess changes in FcRn's functional status in cachectic tumor-bearing mice.
RESULTS: We noted that the induction of IgG clearance in the presence of a cachectic tumor was dampened by the lack of FcRn engagement in whole body FcRn knockout mice. As expected, clodronate administration did not significantly affect systemic clearance of FcRn-binding IgG, though it significantly reduced clearance of FcRn-null IgG. More importantly, these effects were consistent in both TF and TB cachectic contexts.
CONCLUSIONS: These results suggest that while FcRn accounts for a portion of the observed changes in IgG pharmacokinetics in cancer cachexia, the functional status of FcRn is not significantly different in healthy mice without tumors compared to those with LLC tumors and associated cachexia, which indicates the potential involvement of FcRn-independent mechanisms.